Gene · 779
CACNA1S: calcium voltage-gated channel subunit alpha1 S
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CACNA1S: calcium voltage-gated channel subunit alpha1 S. Genes, record 779. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/779
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q13698 | Voltage-dependent L-type calcium channel subunit alpha-1S | 1,873 | 2 | Ensembl, GeneID, HGNC |
Source UniProt
Patents21
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 39649 | Q13698 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 8139 | Q13698 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 696 | Q13698 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 696 | Q13698 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 8139 | Q13698 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 10758 | Q13698 | Espacenet |
| JP 2025510310 A | 2025-04-14 | 1 | Q13698 | Espacenet |
| KR 1020240163152 A | 2024-11-18 | 1 | Q13698 | Espacenet |
| US 12077582 B2 | 2024-09-03 | 8 | Q13698 | Espacenet |
| US 11492400 B2 | 2022-11-08 | 8 | Q13698 | Espacenet |
1 to 10 of 21
See all 21 patentsDrugs45
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AMLODIPINE | CHEMBL1491 | Voltage-gated L-type calcium channel blocker | BLOCKER | ChEMBL |
| AMLODIPINE BENZOATE | CHEMBL4594262 | Voltage-gated L-type calcium channel blocker | BLOCKER | ChEMBL |
| AMLODIPINE BESYLATE | CHEMBL1200402 | Voltage-gated L-type calcium channel blocker | BLOCKER | ChEMBL |
| AMLODIPINE MALEATE | CHEMBL1200984 | Voltage-gated L-type calcium channel blocker | BLOCKER | ChEMBL |
| ATAGABALIN | CHEMBL593430 | Voltage-gated calcium channel modulator | MODULATOR | ChEMBL |
| AZD1305 | CHEMBL3545169 | Voltage-gated L-type calcium channel blocker | BLOCKER | ChEMBL |
| AZELNIDIPINE | CHEMBL1275868 | Voltage-gated L-type calcium channel blocker | BLOCKER | ChEMBL |
| BARNIDIPINE | CHEMBL2103761 | Voltage-gated L-type calcium channel blocker | BLOCKER | ChEMBL |
| BENIDIPINE | CHEMBL2074972 | Voltage-gated L-type calcium channel blocker | BLOCKER | ChEMBL |
| BEPRIDIL | CHEMBL1008 | Voltage-gated calcium channel blocker | BLOCKER | ChEMBL |
1 to 10 of 45
See all 45 drugsTrials965
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07606638 | PREGABALIN | ClinicalTrials.gov | ||
| NCT07603037 | NICARDIPINE | ClinicalTrials.gov | ||
| NCT07598474 | PREGABALIN | ClinicalTrials.gov | ||
| NCT07564726 | AMLODIPINE | PHASE3 | ClinicalTrials.gov | |
| NCT07458880 | AMLODIPINE | ClinicalTrials.gov | ||
| NCT07448506 | NIFEDIPINE | PHASE3 | ClinicalTrials.gov | |
| NCT07429734 | GABAPENTIN | PHASE3 | ClinicalTrials.gov | |
| NCT07420166 | VERAPAMIL HYDROCHLORIDE | ClinicalTrials.gov | ||
| NCT07382921 | PREGABALIN | ClinicalTrials.gov | ||
| NCT07364201 | NICARDIPINE | ClinicalTrials.gov |
1 to 10 of 965
See all 965 trialsNIH grants1,381
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CACNA1S papers | Newest fiscal year |
|---|---|---|---|
| R01AR063182 | Disease Pathogenesis and Modification for CaV1.1-Associated Hypokalemic Periodic Paralysis | 9 | 2025 |
| T32AR007592 | Interdisciplinary Training Program in Muscle Biology | 7 | 2025 |
| U01HG006379 | EHR-based Genomic Discovery and Implementation [Funded Extension] | 7 | 2025 |
| P30AG021332 | Wake Forest Claude D. Pepper OAIC - Renewal | 6 | 2025 |
| R01ES014901 | Molecular and Cellular Basis of PCB Developmental Neurotoxicity | 5 | 2025 |
| R01HL112808 | Structural Basis for Antiarrhythmic Drug Action | 5 | 2025 |
| R01HL140934 | Exploring the Molecular Physiology of Atrial Fibrillation | 5 | 2025 |
| ZIAHG200359 | Genomic Ascertainment - Molecular and Genetic Aspects | 5 | 2025 |
| K24HL133373 | Discovery, Implementation and Mentorship in Personalized Cardiovascular Pharmacotherapy | 4 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 4 | 2025 |
1 to 10 of 1,381Source NIH's project files
See all 1,381 nih grantsPapers2,128
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Estimating the Prevalence of Malignant Hyperthermia Susceptibility Based on Causative RYR1 and CACNA1S Variants. | Int J Mol Sci | 2026 | 42794754 | PubTator, text mining | PubMed |
| A New Disease Gene for Hypokalemic Periodic Paralysis, KCNA7 , Established in a Multigenerational Family. | bioRxiv | 2026 | 42780157 | PubTator, text mining | PubMed |
| Generation of two human induced pluripotent stem cell lines from patients with hypokalemic periodic paralysis. | Stem Cell Res | 2026 | 42759100 | PubTator, text mining | PubMed |
| A novel CACNA1S variant associated with diltiazem-related worsening of hypokalemic periodic paralysis: a case report. | Neurol Sci | 2026 | 42637926 | PubTator, text mining | PubMed |
| Molecular genetics of skeletal muscle diseases associated with abnormal excitation-contraction coupling. | J Hum Genet | 2026 | 42572084 | PubTator, text mining | PubMed |
| Managing Secondary Findings from Germline Pharmacogenomic Testing. | J Pers Med | 2026 | 42506114 | PubTator, text mining | PubMed |
| Allosteric interactions between RyR channels justify intracellular Ca2+ release of skeletal muscle in quantitative detail. | J Gen Physiol | 2026 | 42479471 | PubTator, text mining | PubMed |
| The genetic basis of over-retained deciduous teeth and delayed permanent tooth eruption: A systematic review. | Am J Orthod Dentofacial Orthop | 2026 | 42446440 | PubTator, text mining | PubMed |
| Gene Panel Analysis Reveals Overlapping Genetic Causes of Inherited Cataracts and Other Ocular Phenotypes in Bulgarian Patients. | Mol Genet Genomic Med | 2026 | 42360812 | PubTator, text mining | PubMed |
| Hypokalemic Periodic Paralysis in a Young Woman With Mast Cell Activation Syndrome: A Case Report of an Atypical Presentation Associated With an Ultra-Rare CACNA1S Variant. | Clin Case Rep | 2026 | 42256938 | PubTator, text mining | PubMed |
1 to 10 of 2,128
See all 2,128 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/779
GET https://conductscience.org/api/genes/v1/779/patents?page=2